Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Phase 2 Trial

October 22, 2026

ImmunoForge Sets the Stage for Innovation at BIO-Europe 2026

Advancing the Future of Oncology As the global biotech community prepares for the upcoming BIO-Europe 2026 conference, ImmunoForge has announced its intention to showcase significant advancements in its therapeutic portfolio. The company is set to present its proprietary platform technologies and share critical updates regarding its next-generation oncology research and development efforts. Focusing on Clinical…

Announcements

BIO-Europe, Biotech, clinical trials, ImmunoForge, oncology, Phase 2 Trial, pr-newswire
October 15, 2026

Bold Therapeutics Hits Key Milestone in Phase 2 Trial for Metastatic Colorectal Cancer

A Significant Step Forward in Cancer Research Bold Therapeutics has officially announced a major achievement in its clinical development program: the company has reached the enrollment midpoint for its randomized Phase 2 clinical trial evaluating BOLD-100. This trial is specifically focused on patients battling second-line metastatic colorectal cancer (mCRC). Understanding the Potential of BOLD-100 BOLD-100…

Announcements

Bold Therapeutics, BOLD-100, Colorectal Cancer, mCRC, oncology, Phase 2 Trial, pr-newswire

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email